Mr. Speaker, in the recent innovation strategy, the Minister of Industry stated that he wanted to resolve potential challenges to investment in Canada before they developed. However, his own actions concerning the violation of the Patent Act in the purchase of Cipro have prompted questions from around the world about the safety of research and development investment in Canada.
How can the minister restore private sector confidence in the Canadian business climate when his own decision, one he was warned against taking by his own department officials, countered the spirit of R and D and innovation in Canada?